Researchers at the Children’s Hospital of Philadelphia (CHOP) have identified a novel gene, BSN, associated with epilepsy and neurodevelopmental disorders. The study marks a crucial step toward improving diagnostics and developing targeted treatments.
Discovery Sparked by Clinical Cases
As reported by medicalxpress, the research began when the Epilepsy Neurogenetics Initiative (ENGIN) team at CHOP identified BSN gene variants in two pediatric epilepsy patients. These were de novo variants, meaning the mutations occurred spontaneously rather than being inherited. Sarah M. Ruggiero, a licensed genetic counselor with ENGIN, noticed the pattern. Motivated by this finding, the team expanded their search and discovered more patients with similar BSN variants—reported here for the first time.
A Synaptic Link: The Role of the BSN Gene
The BSN gene produces Bassoon, a protein critical for synapse function in the brain. Its name comes from the stick-like appearance resembling the musical instrument. Though previously linked to brain disorders, very few clinical cases had been reported until now.
Powerful Data Integration and Analysis
To investigate further, researchers utilized data from multiple sources including the Penn Medicine BioBank, the CHOP Birth Defects Biorepository, and the Center for Applied Genomics (CAG). This was the first study to incorporate data from CHOP’s Birth Defects Biorepository. Using the Human Phenotype Ontology (HPO), they standardized clinical data and identified 29 individuals with disruptive BSN variants.
Unique Clinical Patterns Emerged
Epilepsy appeared in 45% of the cases, followed by febrile seizures (25%), generalized tonic-clonic seizures (17%), and focal seizures (10%). Developmental delays (38%), ADHD (25%), autism-like behaviors (17%), obesity (34%), and delayed speech (28%) were also common.
Future Implications
According to Dr. Ingo Helbig, senior study author, this big-data approach provides a roadmap for understanding the broader impact of rare genetic disorders and lays the groundwork for future clinical trials.